Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer

References

• Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem.237(6) 1555–1562 (1962).
   PubMed Web of Science ®Google Scholar
• Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor–protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem.255(10), 4834–4842 (1980).
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol.19(3), 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Barnes D, Sato G. Serum-free cell culture: a unifying approach. Cell22(3), 649–655 (1980).
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Sato JD, Le A et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA80(5), 1337–1341 (1983).
   PubMed Web of Science ®Google Scholar
• Sato JD, Kawamoto T, Le AD et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med.1(5), 511–529 (1983).
   PubMedGoogle Scholar
• Masui H, Kawamoto T, Sato JD et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.44(3), 1002–1007 (1984).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol.22(5), 777–784 (2004).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J. Clin. Oncol.23(Suppl. Pt 1), S16 (2005) (Abstract 1).
   Google Scholar
• Normanno N, Bianco C, Strizzi L et al. The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets6(3), 243–257 (2005).
   PubMed Web of Science ®Google Scholar
• Saito T, Okada S, Ohshima K et al. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology145(9), 4232–4243 (2004).
   PubMed Web of Science ®Google Scholar
• Tzahar E, Waterman H, Chen X et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol.16(10), 5276–5287 (1996).
   PubMed Web of Science ®Google Scholar
• Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer8(1), 11–31 (2001).
   PubMed Web of Science ®Google Scholar
• Wu W, Graves LM, Gill GN, Parsons SJ, Samet JM. Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. J. Biol. Chem.277(27), 24252–24257 (2002).
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Lemmon MA. SH2 and PTB domains in tyrosine kinase signaling. Sci. STKE2003(191), RE12 (2003).
   PubMedGoogle Scholar
• Pawson T, Olivier P, Rozakis-Adcock M, McGlade J, Henkemeyer M. Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways. Philos. Trans. R. Soc. Lond.340(1293), 279–285 (1993).
   PubMed Web of Science ®Google Scholar
• Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res.63(14), 3923–3930 (2003).
   PubMed Web of Science ®Google Scholar
• Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res.8(4), 945–954 (2002).
   PubMed Web of Science ®Google Scholar
• Lund KA, Lazar CS, Chen WS et al. Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. J. Biol. Chem.265(33), 20517–20523 (1990).
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology146(11), 4609–4618 (2005).
   PubMed Web of Science ®Google Scholar
• Busse D, Doughty RS, Ramsey TT et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J. Biol. Chem.275(10), 6987–6995 (2000).
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer37(Suppl. 4), S3–S8 (2001).
   PubMed Web of Science ®Google Scholar
• Lenferink AE, Pinkas-Kramarski R, van de Poll ML et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J.17(12), 3385–3397 (1998).
   PubMed Web of Science ®Google Scholar
• Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist10(4), 250–261 (2005).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer37(Suppl. 4), S9–S15 (2001).
   PubMedGoogle Scholar
• Zhang W, Park DJ, Lu B et al. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin. Cancer Res.11(2 Pt 1), 600–605 (2005).
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim JM, Li S et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys.66(1), 195–200 (2006).
   PubMed Web of Science ®Google Scholar
• Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl Acad. Sci. USA83(11), 3825–3829 (1986).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Venook A, Niedzweiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX){±} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol.24, S148 (2006) (Abstract 3509).
   Google Scholar
• Gibson TB, Ranganathan A, Grothey A. Randomized Phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer6(1), 29–31 (2006).
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol.22(1), 175–184 (2004).
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa®). Curr. Opin. Oncol.13(6), 491–498 (2001).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, LaFleur B, Levy DE et al. Randomized Phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol.23(36), 9265–9274 (2005).
   PubMed Web of Science ®Google Scholar
• Townsley CA, Major P, Siu LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br. J. Cancer94(8), 1136–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Laheru DA, Senzer NN et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin. Cancer Res.10(19), 6522–6527 (2004).
   PubMed Web of Science ®Google Scholar
• Veronese ML, Sun W, Giantonio B et al. A Phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br. J. Cancer92(10), 1846–1849 (2005).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am. J. Oncol.28(4), 340–344 (2005).
   PubMed Web of Science ®Google Scholar
• Knight LA, Di Nicolantonio F, Whitehouse P et al. The in vitro effect of gefitinib (‘Iressa’) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer4, 83 (2004).
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother. Oncol.76(2), 157–161 (2005).
   PubMed Web of Science ®Google Scholar
• Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res.64(15), 5355–5362 (2004).
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Atkins D, Reiffen KA, Tegtmeier CL et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem.52(7), 893–901 (2004).
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol.22(23), 4772–4778 (2004).
   PubMed Web of Science ®Google Scholar
• Mutsaers AJ, Ebos JM, Lee C, et al. Circulating levels of ligand as a potential biomarker for optimal dosing of targeted antibody drugs to the epidermal growth factor receptor. Presented at: 18th EORTC–NCI–AACR Symposium (2006) (Abstract 217).
   Google Scholar
• Zhang W, Gordon M, Press OA et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet. Genomics16(7), 475–483 (2006).
   PubMed Web of Science ®Google Scholar
• Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int. J. Radiat. Oncol. Biol. Phys.58(3), 914–926 (2004).
   PubMed Web of Science ®Google Scholar
• Mimori K, Yamashita K, Ohta M et al. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells. Clin. Cancer Res.10(24), 8243–8249 (2004).
   PubMed Web of Science ®Google Scholar
• Prenzel N, Zwick E, Daub H et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature402(6764), 884–888 (1999).
   PubMed Web of Science ®Google Scholar
• Cunningham MP, Essapen S, Thomas H et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int. J. Oncol.28(2), 329–335 (2006).
   PubMed Web of Science ®Google Scholar
• Azuma M, Danenberg KD, Iqbal S et al. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin. Colorectal Cancer6(3), 214–218 (2006).
   PubMed Web of Science ®Google Scholar
• Li B, Yuan M, Kim IA et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene23(26), 4594–4602 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med.351(27), 2883 (2004).
   PubMed Web of Science ®Google Scholar
• Nagahara H, Mimori K, Ohta M et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res.11(4), 1368–1371 (2005).
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol.24(30), 4914–4921 (2006).
   PubMed Web of Science ®Google Scholar
• Yang SH, Mechanic LE, Yang P et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res.11(6), 2106–2110 (2005).
   PubMed Web of Science ®Google Scholar
• Liu W, Innocenti F, Chen P et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res.9(3), 1009–1012 (2003).
   PubMed Web of Science ®Google Scholar
• Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res.64(24), 9139–9143 (2004).
   PubMed Web of Science ®Google Scholar
• Buerger H, Packeisen J, Boecker A et al. Allelic length of a CA dinucleotide repeat in the EGFR gene correlates with the frequency of amplifications of this sequence – first results of an inter-ethnic breast cancer study. J. Pathol.203(1), 545–550 (2004).
   PubMed Web of Science ®Google Scholar
• Sauer T, Guren MG, Noren T, Dueland S. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology47(6), 560–564 (2005).
   PubMed Web of Science ®Google Scholar
• Petrova D, Jankova R, Yosifova A et al. Tissue microarray analysis of EGFR gene amplification and gain in Bulgarian patients with colorectal cancer. Onkologie29(5), 198–200 (2006).
   PubMedGoogle Scholar
• Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol.6(5), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
   PubMed Web of Science ®Google Scholar
• Personeni N, Hendlisz A, Gallez J et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin. Oncol.32(6 Suppl. 9), 59–62 (2005).
   Web of Science ®Google Scholar
• Personeni NDS, De Hertogh J, Debiec-Rychter G et al. Response prediction to cetuximab-based therapy: the role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations. Presented at: Gastrointestinal American Society of Clinical Oncology. FL, USA (2007) (Abstract 400).
   Google Scholar
• Romagnani EM, Ghisletta V, Camponovo M et al. EGFR gene status, K-Ras mutation and PTEN expression predict cetuximab response in metastatic colorectal cancer (mCRC). Presented at: Gastrointestinal American Society of Clinical Oncology. FL, USA (2007) (Abstract 427).
   Google Scholar
• Vallbohmer D, Zhang W, Gordon M et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol.23(15), 3536–3544 (2005).
   PubMed Web of Science ®Google Scholar
• Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin. Cancer Res.11(20), 7480–7489 (2005).
   PubMed Web of Science ®Google Scholar
• Cunningham MP, Essapen S, Thomas H et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int. J. Oncol.27(2), 317–325 (2005).
   PubMed Web of Science ®Google Scholar
• Jones HE, Gee JM, Taylor KM et al. Development of strategies for the use of anti-growth factor treatments. Endocr. Relat. Cancer12(Suppl. 1), S173–S182 (2005).
   PubMed Web of Science ®Google Scholar
• Kong A, Leboucher P, Leek R et al. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res.66(5), 2834–2843 (2006).
   PubMed Web of Science ®Google Scholar
• Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol.30(10), 1128–1133 (1999).
   PubMed Web of Science ®Google Scholar
• Adams TE, McKern NM, Ward CW. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors22(2), 89–95 (2004).
   PubMed Web of Science ®Google Scholar
• Morelli MP, Cascone T, Troiani T et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J. Cell Physiol.208(2), 344–353 (2006).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz H, Hochster H et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecanrefractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 3508).
   Google Scholar
• Adam L, Black G, Brown M et al. EGFR and PDGFR crosstalk may dictate the resistance to EGFR therapy in bladder cancer. Eur. J. Cancer (Suppl.) 64 (2006).
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature445(7126), 437–441 (2007).
   PubMed Web of Science ®Google Scholar
• Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochimie Biologie Cellulaire82(2), 263–274 (2004).
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res.49(17), 4682–4689 (1989).
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol.22(13), 2610–2616 (2004).
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol.72(3), 257–266 (2004).
   PubMed Web of Science ®Google Scholar
• Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann HP. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K–AKT pathway. Radiother. Oncol.76(2), 143–150 (2005).
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Sasamoto H, Notohara K et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J. Clin. Oncol.22(22), 4584–4594 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer – more than skin deep. J. Clin. Oncol.23(23), 5374–5385 (2005).
   PubMed Web of Science ®Google Scholar
• Hoshino R, Chatani Y, Yamori T et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene18(3), 813–822 (1999).
   PubMed Web of Science ®Google Scholar
• Philp AJ, Campbell IG, Leet C et al. The phosphatidylinositol 3´-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res.61(20), 7426–7429 (2001).
   PubMed Web of Science ®Google Scholar
• Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell cycle3(10), 1221–1224 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham MP, Thomas H, Fan Z, Modjtahedi H. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res.66(15), 7708–7715 (2006).
   PubMed Web of Science ®Google Scholar
• Ogino S, Meyerhardt JA, Cantor M et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin. Cancer Res.11(18), 6650–6656 (2005).
   PubMed Web of Science ®Google Scholar
• Salazar RT, Rojo J, Jimenez E et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 2002).
   PubMedGoogle Scholar
• Cappuzzo F, Magrini E, Ceresoli GL et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl Cancer Inst.96(15), 1133–1141 (2004).
   PubMed Web of Science ®Google Scholar
• Bianco R, Shin I, Ritter CA et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene22(18), 2812–2822 (2003).
   PubMed Web of Science ®Google Scholar
• Goel A, Arnold CN, Niedzwiecki D et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res.64(9), 3014–3021 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou XP, Loukola A, Salovaara R et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol.161(2), 439–447 (2002).
   PubMed Web of Science ®Google Scholar
• Corvinus FM, Orth C, Moriggl R et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia7(6), 545–555 (2005).
   PubMed Web of Science ®Google Scholar
• Lin Q, Lai R, Chirieac LR et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol.167(4), 969–980 (2005).
   PubMed Web of Science ®Google Scholar
• Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell1(5), 445–457 (2002).
   PubMed Web of Science ®Google Scholar
• Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin. Orthop. Relat. Res. (415 Suppl.), S46–S58 (2003).
   Google Scholar
• Yauch RL, Januario T, Eberhard DA et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res.11(24 Pt 1), 8686–8698 (2005).
   PubMed Web of Science ®Google Scholar
• Torrance CJ, Jackson PE, Montgomery E et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med.6(9), 1024–1028 (2000).
   PubMed Web of Science ®Google Scholar
• Jimeno A, Rubio-Viqueira B, Amador ML et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res.65(8), 3003–3010 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol.23(22), 5235–5246 (2005).
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Ettenberg SA et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell4(6), 1029–1040 (1999).
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Zamir E et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev.12(23), 3663–3674 (1998).
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho HS, Eigenbrot C et al. An open and shut case? Recent insights into the activation of EGFR/ErbB receptors. Mol. Cell12(3), 541–552 (2003).
   PubMed Web of Science ®Google Scholar